Sign in
CHMMF Stock Price, Chart, Stats & News
Chimeric Therapeutics Limited
Save
Chimeric Therapeutics Limited (CHMMF) does not currently pay a dividend.
4.10M
Market cap
–
Current P/E
–
Forward P/E
CHMMF chart
About
Health care
Sector
Biotechnology
Industry
Chimeric Therapeutics Limited is an Australian biotechnology firm operating at the clinical stage, dedicated to advancing and commercializing a diverse portfolio of cell-based treatments specifically for cancer. Its pipeline features several promising candidates. CHM 0201, utilizing a core natural killer (NK) cell platform, is currently undergoing Phase I clinical trials for the treatment of both solid tumors and hematological malignancies.
Similar securities
Based on sector and market capitalization
Report issue